Tacrolimus and quality of life after kidney transplantation - a multicenter study
- 1 July 2006
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 20 (4) , 504-508
Abstract
Kidney transplantation is currently the treatment of choice for end-stage renal disease. Although new immunosuppressive drugs have been introduced into clinical practice, the effect of such medication on quality of life (QoL) in transplant recipients is still unclear. The present study analyzes the impact of tacrolimus-based immunosuppression on QoL in a representative sample of adult kidney transplant recipients from Rio Grande do Sul, a Brazilian southern state. This was a cross-sectional multicenter study which used the SF-36 Health Survey for measuring QoL. The effect of tacrolimus on QoL was adjusted for possible confounders using multiple linear regression. A total of 272 patients (from 11 different centers) were evaluated, 48 of them were treated with tacrolimus. Transplant patients in use of tacrolimus presented significant higher scores in the physical component summary of SF-36 than non-users (49.1+/-8.3 vs. 46.1+/-8.7; p=0.03), and such difference was noted in the physical functioning and general health subscales (81.5+/-17.1 and 74.7+/-21.8; 74.6+/-22.3 and 67.1+/-22.3 for users and non-users of tacrolimus, respectively, p<0.05). The effect of tacrolimus remained significant after adjustment for age, gender, skin color and time since transplantation (coeff.: 2.83; 95% CI: 0.05-5.6, p=0.045). The association between tacrolimus-based immunosuppression and better perception of physical functioning and general health for renal transplant patients represents a significant finding as it may influence therapeutical decisions and contribute to maximize kidney transplantation benefits.Keywords
This publication has 12 references indexed in Scilit:
- Pharmacoepidemiology of Anemia in Kidney Transplant RecipientsJournal of the American Society of Nephrology, 2004
- Strategies to Improve Long-Term Outcomes after Renal TransplantationNew England Journal of Medicine, 2002
- Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine‐microemulsionClinical Transplantation, 2002
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- COMPLIANCE AND NONCOMPLIANCE IN PATIENTS WITH A FUNCTIONING RENAL TRANSPLANT: A MULTICENTER STUDY1,2Transplantation, 1998
- ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN KIDNEY TRANSPLANT PATIENTS RECEIVING TACROLIMUS (FK506)-BASED VERSUS CYCLOSPORINE-BASED IMMUNOSUPPRESSION1,2Transplantation, 1997
- MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1Transplantation, 1997
- Mode of Action of Tacrolimus (FK506): Molecular and Cellular MechanismsTherapeutic Drug Monitoring, 1995
- Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejectionThe Lancet, 1994
- The Quality of Life of Patients with End-Stage Renal DiseaseNew England Journal of Medicine, 1985